{"id":"W4318904300","doi":"10.1200/jco.2023.41.4_suppl.394","title":"Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Cancer; Clinical endpoint; Adverse effect; Clinical trial; Oncology; Discontinuation; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002489077,0.0001390731,0.001742556,0.0003536152,0.0000307701,0.00000552047,0.0003208427,0.0001991355,0.0001095674],"category_scores_gemma":[0.00295188,0.00008542178,0.0006763606,0.001060037,0.0001734401,0.00009446281,0.000131235,0.0008542368,0.000008727328],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000238532,"about_ca_system_score_gemma":0.001953786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004704038,"about_ca_topic_score_gemma":0.00005479282,"domain_scores_codex":[0.9961078,0.000306991,0.00254833,0.0001822226,0.0005399663,0.0003147263],"domain_scores_gemma":[0.9962457,0.001159503,0.001954271,0.0002593905,0.0002229843,0.000158153],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.25558,0.005496903,0.179477,0.0001785484,0.0006184517,0.001268408,0.0002018872,0.0008188285,0.00129128,0.0001240666,0.01417059,0.5407741],"study_design_scores_gemma":[0.4473878,0.01843969,0.5024235,0.0002068993,0.0004668602,0.00006872544,0.0002281573,0.0005536965,0.00005566746,0.0001158837,0.02996147,0.00009171616],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831985,0.0002667167,0.00003890991,0.01025356,0.004297572,0.0005093121,0.000005648812,0.00001202261,0.001417815],"genre_scores_gemma":[0.9935393,0.003581829,0.0002011256,0.0007871966,0.001160561,0.000007232141,0.000002875239,0.0000153074,0.0007045339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5406824,"threshold_uncertainty_score":0.3711281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1358713147359017,"score_gpt":0.5253662221665132,"score_spread":0.3894949074306114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}